Drug intelligence / Profile preview

AMG 691

Development stage: Phase 1
Lead developer: Amgen
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Subcutaneous

Overview

AMG 691 is a monoclonal antibody being developed by Amgen for the treatment of asthma. It is administered as a subcutaneous injection and is currently in Phase 1 clinical trials to evaluate its safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy participants and those with mild-to-moderate asthma. The precise mechanism of action has not been disclosed. Its primary indication under investigation is asthma within the broader therapeutic areas of immune system diseases and respiratory diseases[1][3][5][7].

Beyond the preview

Go deeper on AMG 691.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AMG 691.

Explore the full profile